Abstract:
The present invention relates to the efficient treatment of an individual afflicted with attention deficit hyperactivity disorder (ADHD), the instant treatment comprising administering to the individual an effective amount of sarizotan or a pharmaceutically acceptable salt thereof.
Abstract:
A formulation free of protein which stabilizes pharmaceutical active proteins, peptides, or mixtures thereof in large scale production processes comprising a mixture of a hydrophilic polymer and a non-ionic detergent, and a mixture of a polyalcohol and a sugar. In some embodiments the polyalcohol is absent.
Abstract:
The invention concerns the use of a sterilization agent comprising H 2 O 2 or a derivative thereof, capable of generating H 2 O 2 as the sterilising component under sterilization conditions, for enhancing the hemocompatibility of objects.
Abstract translation:本发明涉及在灭菌条件下能够产生H 2 O 2作为灭菌成分的包含H 2 O 2或其衍生物的灭菌剂用于提高物体的血液相容性的用途。
Abstract:
A method for treating a disease or condition caused by or associated with hyperactivity of muscles or exocrine glands in a patient, the method comprising administering a composition comprising an effective amount of Clostridium botulinum toxin, wherein the composition is administered in such a way to the treated hyperactive cholinergic innervated muscle or gland that the of symptoms is kept stable during the whole treatment period.
Abstract:
Sorbent comprising a solid support material, the surface of which comprises a first residue comprising a pyridyl ring, whose hydrogen atoms may be substituted, and a second residue comprising a carboxyl group.
Abstract:
The present invention relates to chemodenervating agents that are modified to carry different functional modulators via specific linker groups. In one embodiment said chemodenervating agent is botulinum toxin. Claimed by this invention is a modified polypeptide wherein the polypeptide is represented by formula I: NT[-NH m (-W) n ] 1 k wherein NT represents a biologically active neurotoxic component or fragment thereof, which is still capable of cleaving proteins of the SNARE complex and of binding to the native HC domain receptor as well as to translocate the light chain; NHm represents an amino group of NT; W represents a residue comprising at least one moiety that is negative charged at physiological pH; m represents an integer of 0, 1 or 2; n represents an integer of 1, 2 or 3 and (m + n) = 2 or 3; k represents an integer of 1 to 1000 wherein for k > 1, each set of m, W and n can be equal or different from each other; i represents a positive charge if (m + n) is 3,wherein if (m+n) is 2 then i represents no charge.
Abstract:
Sorbent comprising a solid support material, the surface of which comprises first residues comprising a binuclear heteroaromatic structure comprising besides carbon atoms at least one of the heteroatoms N, O, S, and second residues comprising a mononuclear heteroaromatic structure comprising besides carbon atoms at least one of the heteroatoms N, O, S.
Abstract:
Method of preparing 3,3,5,5-tetramethylcyclohexanone comprising step (i): (i) converting isophorone to 3,3,5,5-tetramethylcyclohexanone in the presence of methylmagnesium chloride. The thus prepared 3,3,5,5-tetramethylcyclohexanone may be employed in a method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane (Neramexane) or a pharmaceutically acceptable salt thereof.
Abstract:
Method of preparing 1-hydroxy-1,3,3,5,5-pentamethylcyclohexane comprising step (ii): (ii) converting 3,3,5,5-tetramethylcyclohexanone to 1-hydroxy-1,3,3,5,5- pentamethylcyclohexane by using methylmagnesium chloride. 1-hydroxy-1,3,3,5,5- pentamethylcyclohexane may be used for preparing 1-amino-1,3,3,5,5- pentamethylcyclohexane (Neramexane) or a pharmaceutically acceptable salt thereof.